New approaches to the assessment of vaccine herd protection in clinical trials

The Lancet Infectious Diseases

Volumn 11, Issue 6, 2011, Pages 482-487

  Clemens, John ^a   Shin, Sunheang ^a   Ali, Mohammad ^a  

^a International Vaccine Institute   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN B SUBUNIT; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PERTUSSIS VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE; TYPHOID VACCINE;

CHOLERA; CLINICAL TRIAL (TOPIC); CLUSTER ANALYSIS; GEOGRAPHIC DISTRIBUTION; HEALTH CARE POLICY; HEALTH PROGRAM; HERD IMMUNITY; HUMAN; INFECTION RISK; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TYPHOID FEVER; VACCINATION;

CLINICAL TRIALS AS TOPIC; COMMUNICABLE DISEASES; HUMANS; IMMUNITY, HERD; RESEARCH DESIGN; VACCINES;

EID: 79956275518     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(10)70318-2     Document Type: Note

References (47)

1. Anderson R, May R Vaccination and herd immunity to infectious diseases. Nature 1985, 318:323-329.
2. Schlenker T, Baine C, Baaughman A, Hadler S Measles herd immunity. The association of attack rates with immunization rates in preschool children. JAMA 1992, 267:823-826.
3. Black F The role of herd immunity in the control of measles. Yale J Biol Med 1982, 55:351-360.
4. Fox J Herd immunity and measles. J Infect Dis 1983, 5:463-466.
5. Fine P, Carneiro I Transmissibility and persistence of oral polio vaccine viruses: Implications for the Global Poliomyelitis Eradiation Initiative. Am J Epidemiol 1999, 150:1001-1021.
6. Bottiger M A study of the sero-immunity that has protected the Swedish population against poliomyelitis for 25 years. Scand J Infect Dis 1987, 19:595-601.
7. Preziosi M, Yam A, Wassilak S, et al. Epidemiology of pertussis in a West African community before and after introduction of a wide-spread vaccination program. Am J Epidemiol 2002, 155:891-896.
8. Trollfors B, Taranger J, Lagergard T, et al. Immunization of children with pertussis toxoid decreases spread of pertussis with the family. Pediatr Infect Dis J 1998, 17:196-199.
9. Miller LW, Older J, Drake J, et al. Diphtheria immunization: effect upon carriers and the control of outbreaks. Am J Dis Child 1972, 123:197-199.
10. McVernon J, Ramsay M, McLean A, et al. Understanding the impact of Hib conjugate vaccine on transmission, immunity and disease in the United Kingdom. Epidemiol Infect 2008, 136:800-812.
11. Reichert T, Sugaya N, Fedson D, Glezen WP, Simonsen L, Tashiro M The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001, 344:889-896.
12. Whitney C, Farley M, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348:1737-1746.
13. Vesikari T, Matson D, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354:23-33. for the Rotavirus Efficacy and Safety Trial (REST) Study Team.
14. Ruiz-Palacios G, Perez-Schael I, Velazquez F, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354:11-14. for the Human Rotavirus Vaccine Study Group.
15. Black S, Shinefield H, Baxter R, et al. Impact of the use of heptavalent pneumococcal conjugate vaccine on disease epidemiology in children and adults. Vaccine 2006, 24(suppl 2):79-80.
16. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blinded, randomised controlled trial. Lancet 2007, 369:2161-2170. for the HPV PATRICIA study group.
17. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 12, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007, 369:1693-1702.
18. Trotter C, Edmunds W Re-assessing the cost-effectiveness of meningococcal serogroup C conjugate (MDD) vaccines using a transmission dynamic model. Med Decis Making 2006, 26:39-47.
19. Longini I, Nizam A, Ali M, Yunus M, Shenvi N, Clemens J Controlling endemic cholera with oral vaccines. PLoS Med 2007, 4:e336.
20. Anderson R The concept of herd immunity and the design of community-based immunization programs. Vaccine 1992, 10:928-935.
21. Panagiotopoulos T, Antoniadou I, Valassi-Adam E Increase in congenital rubella occurrence after immunization in Greece: retrospective survey and systematic review. BMJ 1999, 319:1462-1467.
22. Singleton R, Hennessy T, Bulkow L, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007, 297:1784-1792.
23. Paul Y Herd immunity and herd protection. Vaccine 2004, 22:301-302.
24. Fox J, Elveback L, Scott W, Gatewood L, Ackerman E Herd immunity: basic concept and relevance to public health immunization practices. Am J Epidemiol 1995, 141:187-197.
25. Halloran ME, Haber M, Longini IM, Struchiner CJ Direct and indirect effects of vaccine efficacy and effectiveness. Am J Epidemiol 1991, 133:323-331.
26. Halloran ME, Struchiner CJ, Longini IM Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol 1997, 146:789-803.
27. Anderson RM, May RM Immunisation and herd immunity. Lancet 1990, 335:641-645.
28. Schlenker T, Baine C, Baaughman A, Hadler S Measles herd immunity. The association of attack rates with immunization rates in preschool children. JAMA 1992, 267:823-826.
29. Whitney C, Farley M, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348:1737-1746.
30. Dagan R, Melamed R, Muallem M, et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996, 174:1271-1278.
31. Dagan R, Givon-Lavi N, Zamir O, et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis 2002, 185:927-936.
32. Takala A, Santosham M, Meido-Hill J, et al. Vaccination with Haemophilus influenzae type b meningococcal potein conjugate vaccine reduces orphyryngeal carriage of Haemophilus influenzae type b among American Indian children. Pediatr Infect Dis J 1993, 12:593-599.
33. Adegbola RA, Secka O, Lahai G, et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 2005, 366:144-150.
34. Whitney C, Farley M, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348:1737-1746.
35. Clemens J, Brenner R, Rao M, Lowe C, Tafari N Evaluating new vaccines for developing countries: Efficacy or effectiveness?. JAMA 1996, 275:390-397.
36. Hayes RJ, Alexander ND, Bennet S, Cousens SN Design and analysis issues in cluster-randomised trials of interventions against infectious diseases. Stat Methods Med Res 2000, 9:95-116.
37. Trollfors B, Taranger J, Lagergard T, et al. Immunization of children with pertussis toxoid decreases spread of pertussis with the family. Pediatr Infect Dis J 1998, 17:196-199.
38. Moulton L, O'Brien K, Kohberger R, et al. Design of a group-randomised Streptococcus pneumoniae vaccine trial. Control Clin Trials 2001, 22:438-452.
39. O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 2003, 362:355-361.
40. Riolo D, Koopman J, Chick S Methods and description of epidemiologic contact networks. J Urban Health 2001, 78:446-457.
41. Longini I, Sagatelian K, Rid W, Halloran M Optimal vaccine trial design when estimating vaccine efficacy for susceptibility and infectiousness from multiple populations. Stat Med 1998, 17:1121-1136.
42. Donner A, Klar N Design and analysis of cluster randomization trials in health research 2000, Arnold, London.
43. Sur D, Ochiai L, Bhattacharya S, et al. A Cluster Randomised Effectiveness Trial of Vi Typhoid Vaccine in India. N Engl J Med 2009, 361:335-344.
44. Ali M, Emch ME, von Seidlein L, et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 2005, 366:44-49.
45. Emch ME Diarrheal disease risk in Matlab, Bangladesh. Soc Sci Med 1999, 49:519-530.
46. Ali M, Emch ME, Ashley C, Streatfield DK Implementation of a medical geographical information system: concept and uses. J Health Popul Nutr 2001, 19:100-110.
47. Jeuland M, Cook J, Poulos C, Clemens J, Whittington D Cost-effectiveness of new generation oral cholera vaccines: a multi-site analysis. Value Health 2009, 12:899-908.